Dateline City:
KENILWORTH, N.J. & NEW YORK
Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction
KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in
partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase
3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an
investigational oral SGLT-2 inhibitor for the treatment of patients with
type 2 diabetes, met their primary endpoints. The study results showed
statistically significant reductions in A1C (a measure of average blood
glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily).
Language:
English
Contact:
Merck Media Contacts:Doris Li, 908-246-5701orKristen Drake, 908-334-4688orMerck Investor Contact:Justin Holko, 908-740-1879orPfizer Media Contact:Steve Danehy, 212-733-1538orPfizer Investor Contact:Ryan Crowe, 212-733-8160
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: PFE Exchange: NYSE
read more